Compare HIHO & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | HCWB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.7M |
| IPO Year | 1996 | 2021 |
| Metric | HIHO | HCWB |
|---|---|---|
| Price | $0.95 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 62.3K | ★ 70.9K |
| Earning Date | 01-20-2026 | 03-27-2026 |
| Dividend Yield | ★ 13.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,143,000.00 | $422,026.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $0.95 |
| 52 Week High | $2.21 | $20.40 |
| Indicator | HIHO | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.